MedTrace Logo

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

NCT03071042 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-03-06

No results posted yet for this study

Summary

This study evaluated the tolerance, safety and efficacy of Apatinib plus Docetaxel as the second-line treatment in locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma).

Conditions

  • Metastatic Gastric Adenocarcinoma

Interventions

DRUG

Apatinib

Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;

DRUG

Docetaxel

Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Sir Run Run Shaw Hospital

    lead OTHER

Principal Investigators

  • Hongming Pan, MD · The Affiliated Sir Run Run Shaw Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-12-31
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03071042 on ClinicalTrials.gov